


RECEIVED
CENTRAL FAX CENTER
SEP 08 2006

CURRENT LISTING OF CLAIMS

1. (currently amended) A compound according to formula I



wherein (i) ~~R¹, R² and R³ are independently selected from the group consisting of hydrogen, C₁₋₁₀ acyl, C₁₋₁₀ alkoxy carbonyl; or, (ii) R¹ is COR⁴ where COR⁴ is the hydrochloride salt of an amino acid or a dipeptide and R² and R³ are independently hydrogen, C₁₋₁₀ acyl, or C₁₋₁₀ alkoxy carbonyl; and, hydrates, solvates, clathrates thereof; with the proviso that at least one of R¹, R² and R³ is not hydrogen.~~

2. (original) A compound according to claim 1 wherein R¹ is COR⁴, and R⁴ is CH(R⁵)NH₃⁺ Cl⁻ or pyrrolidin-2-yl, R⁵ is selected from the group consisting of CH(CH₃)₂ and CH(CH₃)CH₂CH₃, and both R² and R³ are hydrogen.

3-8. (canceled)

9. (original) A method for modulating Th1 and Th2 immune activity comprising administering to a mammal a therapeutically effective amount of a compound according to Claim 1.

10. (original) A method according to claim 9 wherein R¹ is COR⁴, and R⁴ is CH(R⁵)NH₃⁺ Cl⁻ or pyrrolidin-2-yl, R⁵ is CH(CH₃)₂ or CH(CH₃)CH₂CH₃, and both R² and R³ are hydrogen.

11. (original) A method according to claim 9 wherein R¹ is COR⁴, and R⁴ is CH(R⁵)NH₃⁺ Cl⁻, R⁵ is CH₃, and both R² and R³ are hydrogen.

12. (canceled)

13. (original) The method of Claim 9 wherein the compound is delivered in a dose of between 0.1 and 300 mg/kg of body weight of the patient/day.

14. (original) The method of Claim 9 wherein the compound is delivered in a dose of between 1.0 and 100 mg/kg of body weight of the patient/day.
15. (original) The method of Claim 9 wherein the compound is delivered in a dose of between 1.0 and 50 mg/kg of body weight of the patient/day.
16. (original) The method of claim 9 wherein the mammal is a human.
17. (original) The method of Claim 9 further comprising at least one other immune system modulator.
18. (original) The method of Claim 17 wherein the immune system modulator is an interferon or chemically-derivatized interferon.
19. (original) The method of claim 18 wherein the chemically derivatized interferon is PEG-interferon- α -2a (PEGASYS®) or PEG-interferon- α -2b (PEG-INTRON™).
20. (original) The method of Claim 9 further comprising administering at least one other antiviral, antiparasitic or anticancer compound.
21. (original) A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 and at least one pharmaceutically acceptable carrier and optionally containing excipients.
22. (original) A pharmaceutical composition according to claim 21 wherein R^1 is COR⁴, and R^4 is CH(R⁵)NH₃⁺ Cl⁻, R⁵ is CH(CH₃)₂, CH(CH₃)CH₂CH₃ or CH₃, and both R² and R³ are hydrogen.

* * * * *